Clinical trial · Observational
Alternative Splicing Based Prediction of Chemotherapy Response in Gastric Cancer
A Multicenter Observational Study to Develop and Validate an Alternative Splicing-Based Machine Learning Model for Predicting Response to 5-FU-Based Adjuvant Chemotherapy in Gastric Cancer (VERSA-GC Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to develop a model to predict response to chemotherapy in gastric cancer using RNA splicing information from tumor tissue. By analyzing genetic patterns and applying machine learning, the study seeks to identify patients who are less likely to benefit from treatment, helping guide clinical decision-making.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observational study (no intervention) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Responder
- description
- Patients with stage II/III gastric cancer who did not develop recurrence within 3 years after curative surgery following adjuvant chemotherapy.
- interventionNames
- Other: Observational study (no intervention)
- label
- Non-responder
- description
- Patients with stage II/III gastric cancer who developed recurrence within 3 years after curative surgery following adjuvant chemotherapy.
- interventionNames
- Other: Observational study (no intervention)
Primary outcomes (1)
- measure
- Treatment response based on 3-year recurrence-free survival
- timeFrame
- 3 years after surgery
- description
- Treatment response was defined based on recurrence-free survival (RFS). Patients who developed recurrence within 3 years after curative surgery were classified as non-responders, whereas those without recurrence were classified as responders.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed stage II or III gastric cancer * Underwent curative surgical resection * Received 5-FU-based adjuvant chemotherapy * Availability of tumor tissue samples for analysis Exclusion Criteria: * History of other malignancies * Inadequate or poor-quality tissue samples (e.g., contamination)
References
Publications (0)
Data not yet available